RxDoctor Payments Data

Charles McGee, NP

Nurse Practitioner · Wharton, TXNPI 1811498959

Payments from drug & device makers

$855in general payments, 2019–2025

Across 38 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$282
  • Smith+Nephew$117
  • Amgen$80
  • Exact Sciences$80
  • Paratek Pharmaceuticals, Inc.$66
  • Boehringer Ingelheim$40
  • plus $191 from 9 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 75th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$10,470
Medicare patients
64
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala20$86,699
OzempicSemaglutide85$83,712
TrulicityDulaglutide45$64,301
EliquisApixaban52$45,211
MounjaroTirzepatide26$42,051
JanuviaSitagliptin Phosphate23$36,325
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$28,627
FarxigaDapagliflozin Propanediol17$25,701
JardianceEmpagliflozin14$23,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,687
TradjentaLinagliptin15$17,574
LinzessLinaclotide16$15,269
EntrestoSacubitril/Valsartan13$12,682
Tresiba Flextouch U-200Insulin Degludec13$8,130
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$8,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$17$106,35271 claims
Boehringer IngelheimJardiance, Tradjenta$40$40,93729 claims
AstraZenecaFarxiga, Symbicort$36$31,77239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Wharton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →